{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:50:39Z","timestamp":1777535439457,"version":"3.51.4"},"reference-count":116,"publisher":"Bentham Science Publishers Ltd.","issue":"14","funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grant","doi-asserted-by":"publisher","award":["RGPIN2017-04480"],"award-info":[{"award-number":["RGPIN2017-04480"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2019,8,16]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Leishmania are sandfly-transmitted protozoan parasites that harbour within the macrophages\nof a mammalian host and cause leishmaniasis, a serious zoonotic disease that threatens the lives of millions\nworldwide. Its numerous forms (cutaneous, mucocutaneous, and visceral) are currently treated with a sparse\narsenal of drugs, specifically antimonials, amphotericin B, miltefosine, and paromomycin, for which drug resistance\nand clinical failure are rampant. Medicine is presently trending towards nanotechnology to aid in the successful\ndelivery of drugs. Vehicles such as lipid-based nanocarriers, polymer-based nanoparticles, and metal ions\nand oxides have been previously demonstrated to improve bioavailability of drugs and decrease toxicity for the\npatient. These cutting-edge solutions can be combined with existing active molecules, as well as novel drugs or\nplant extracts with promising antileishmanial activity.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>This review explores the current evidence for the treatment of leishmaniases using nanoscale drug\ndelivery systems (specifically lipid-, polymer- and metal-based systems) and encourages further development of\nthe aforementioned nanotechnologies for treatment of Leishmania.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1381612825666190621154552","type":"journal-article","created":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T09:20:11Z","timestamp":1561108811000},"page":"1582-1592","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Innovative Solutions for the Control of Leishmaniases: Nanoscale Drug Delivery Systems"],"prefix":"10.2174","volume":"25","author":[{"given":"Victoria","family":"Wagner","sequence":"first","affiliation":[{"name":"Departement de Pathologie et Microbiologie, Faculte de Medecine Veterinaire Universite de Montreal, Saint-Hyacinthe, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aida","family":"Minguez-Menendez","sequence":"additional","affiliation":[{"name":"Departement de Pathologie et Microbiologie, Faculte de Medecine Veterinaire Universite de Montreal, Saint-Hyacinthe, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Pena","sequence":"additional","affiliation":[{"name":"Departement de Pathologie et Microbiologie, Faculte de Medecine Veterinaire Universite de Montreal, Saint-Hyacinthe, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Fern\u00e1ndez-Prada","sequence":"additional","affiliation":[{"name":"Departement de Pathologie et Microbiologie, Faculte de Medecine Veterinaire Universite de Montreal, Saint-Hyacinthe, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"1151","volume":"29","author":"Louzir H.","year":"2013","unstructured":"Louzir H.; Aoun K.; Sp\u00e4th G.F.; \n                        Leishmania epidemiology, diagnosis, chemotherapy and vaccination approaches in the international network of Pasteur Institutes. Med Sci [http:\/\/dx.doi.org\/10.1051\/medsci\/20132912020]. [PMID: 24356147].2013,29(12),1151-1160","journal-title":"Med Sci"},{"key":"ref=2","author":"von Stebut E.","year":"2017","unstructured":"von Stebut E.; Tenzer S.; Cutaneous leishmaniasis: Distinct functions of dendritic cells and macrophages in the interaction of the host immune system with Leishmania major. Int J Med Microbiol [PMID: 29129568].2017","journal-title":"Int J Med Microbiol"},{"key":"ref=3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2014.09.014","volume":"73","author":"Handler MZ","year":"2015","unstructured":"Handler MZ; Patel PA; Kapila R; Al-Qubati Y; Schwartz RA; Cutaneous and mucocutaneous leishmaniasis: Differential diagnosis, diagnosis, histopathology, and management J Am Acad Dermatol 2015,73(6)","journal-title":"J Am Acad Dermatol"},{"key":"ref=4","volume":"11","author":"Bush J.T.","year":"2017","unstructured":"Bush J.T.; Wasunna M.; Alves F.; Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: A first step to assess the feasibility of establishing an individual patient data sharing platform. PLoS Negl Trop Dis [http:\/\/dx.doi.org\/10.1371\/journal.pntd.0005781]. [PMID: 28873394].2017,11(9)","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/bmb\/lds031","volume":"104","author":"Barrett M.P.","year":"2012","unstructured":"Barrett M.P.; Croft S.L.; Management of trypanosomiasis and leishmaniasis. Br Med Bull [http:\/\/dx.doi.org\/10.1093\/bmb\/lds031]. [PMID: 23137768].2012,104,175-196","journal-title":"Br Med Bull"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.12688\/f1000research.9218.1","volume":"5","author":"Laffitte M.N.","year":"2016","unstructured":"Laffitte M.N.; Leprohon P.; Papadopoulou B.; Ouellette M.; Plasticity of the Leishmania genome leading to gene copy number variations and drug resistance. F1000 Res [http:\/\/dx.doi.org\/10.12688\/f1000research.9218.1]. [PMID: 27703673].2016,5,2350","journal-title":"F1000 Res"},{"key":"ref=7","first-page":"101","author":"Fernandez-Prada C.","year":"2018","unstructured":"Fernandez-Prada C.; Vincent I.M.; Gazanion E.; Monte-Neto R.L.;  Omics and Their Impact on the Development of Chemotherapy Against Leishmania Drug Discovery for Leishmaniasis 2018,101-129","journal-title":"Omics and Their Impact on the Development of Chemotherapy Against Leishmania Drug Discovery for Leishmaniasis"},{"key":"ref=8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006052","volume":"11","author":"Ponte-Sucre A.","year":"2017","unstructured":"Ponte-Sucre A.; Gamarro F.; Dujardin J.C.; Drug resistance and treatment failure in leishmaniasis: A 21 century challenge. PLoS Negl Trop Dis [http:\/\/dx.doi.org\/10.1371\/journal.pntd.0006052]. [PMID: 29240765].2017,11(12)","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ijpddr.2018.03.004","volume":"8","author":"Fernandez-Prada C.","year":"2018","unstructured":"Fernandez-Prada C.; Sharma M.; Plourde M.; High-throughput Cos-Seq screen with intracellular Leishmania infantum for the discovery of novel drug-resistance mechanisms. Int J Parasitol Drugs Drug Resist [http:\/\/dx.doi.org\/10.1016\/j.ijpddr.2018.03.004]. [PMID: 29602064].2018,8(2),165-173","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"ref=10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005171","volume":"10","author":"Fernandez-Prada C.","year":"2016","unstructured":"Fernandez-Prada C.; Vincent I.M.; Brotherton M.C.; Different Mutations in a P-type ATPase Transporter in Leishmania Parasites are Associated with Cross-resistance to Two Leading Drugs by Distinct Mechanisms. PLoS Negl Trop Dis [http:\/\/dx.doi.org\/10.1371\/journal.pntd.0005171]. [PMID: 27911896].2016,10(12)","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"E3012","DOI":"10.1073\/pnas.1520693113","volume":"113","author":"Gazanion \u00c9.","year":"2016","unstructured":"Gazanion \u00c9.; Fern\u00e1ndez-Prada C.; Papadopoulou B.; Leprohon P.; Ouellette M.; Cos-Seq for high-throughput identification of drug target and resistance mechanisms in the protozoan parasite Leishmania. Proc Natl Acad Sci USA [http:\/\/dx.doi.org\/10.1073\/pnas.1520693113]. [PMID: 27162331].2016,113(21),E3012-E3021","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijpddr.2014.09.005","volume":"5","author":"Leprohon P.","year":"2014","unstructured":"Leprohon P.; Fernandez-Prada C.; Gazanion \u00c9.; Monte-Neto R.; Ouellette M.; Drug resistance analysis by next generation sequencing in Leishmania. Int J Parasitol Drugs Drug Resist [http:\/\/dx.doi.org\/10.1016\/j.ijpddr.2014.09.005]. [PMID: 25941624].2014,5(1),26-35","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1006\/abbi.1997.0126","volume":"342","author":"Wang J.","year":"1997","unstructured":"Wang J.; Leblanc E.; Chang C.F.; Pterin and folate reduction by the Leishmania tarentolae H locus short-chain dehydrogenase\/reductase PTR1. Arch Biochem Biophys [http:\/\/dx.doi.org\/10.1006\/abbi.1997.0126]. [PMID: 9186479].1997,342(2),197-202","journal-title":"Arch Biochem Biophys"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/nar\/gkn1069","volume":"37","author":"Leprohon P.","year":"2009","unstructured":"Leprohon P.; L\u00e9gar\u00e9 D.; Raymond F.; Gene expression modulation is associated with gene amplification, supernumerary chromosomes and chromosome loss in antimony-resistant Leishmania infantum. Nucleic Acids Res [http:\/\/dx.doi.org\/10.1093\/nar\/gkn1069]. [PMID: 19129236].2009,37(5),1387-1399","journal-title":"Nucleic Acids Res"},{"key":"ref=15","volume":"5","author":"do Monte-Neto R.L.","year":"2011","unstructured":"do Monte-Neto R.L.; Coelho A.C.; Raymond F.; Gene expression profiling and molecular characterization of antimony resistance in Leishmania amazonensis. PLoS Negl Trop Dis [http:\/\/dx.doi.org\/10.1371\/journal.pntd.0001167]. [PMID: 21629719].2011,5(5)","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.4161\/viru.2.5.17035","volume":"2","author":"Blecher K.","year":"2011","unstructured":"Blecher K.; Nasir A.; Friedman A.; The growing role of nanotechnology in combating infectious disease. Virulence [http:\/\/dx.doi.org\/10.4161\/viru.2.5.17035]. [PMID: 21921677].2011,2(5),395-401","journal-title":"Virulence"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/nn900002m","volume":"3","author":"Farokhzad O.C.","year":"2009","unstructured":"Farokhzad O.C.; Langer R.; Impact of nanotechnology on drug delivery. ACS Nano [http:\/\/dx.doi.org\/10.1021\/nn900002m]. [PMID: 19206243].2009,3(1),16-20","journal-title":"ACS Nano"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2217\/17435889.3.4.401","volume":"3","author":"Youan B.B.","year":"2008","unstructured":"Youan B.B.; Impact of nanoscience and nanotechnology on controlled drug delivery. Nanomedicine [http:\/\/dx.doi.org\/10.2217\/17435889.3.4.401]. [PMID: 18694301].2008,3(4),401-406","journal-title":"Nanomedicine"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.actatropica.2017.06.025","volume":"174","author":"Tomiotto-Pellissier F.","year":"2017","unstructured":"Tomiotto-Pellissier F.; Miranda-Sapla M.M.; Machado L.F.; Nanotechnology as a potential therapeutic alternative for schistosomiasis. Acta Trop [http:\/\/dx.doi.org\/10.1016\/j.actatropica.2017.06.025]. [PMID: 28668252].2017,174,64-71","journal-title":"Acta Trop"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"5289","DOI":"10.2147\/IJN.S140363","volume":"12","author":"Bruni N.","year":"2017","unstructured":"Bruni N.; Stella B.; Giraudo L.; Della Pepa C.; Gastaldi D.; Dosio F.; Nanostructured delivery systems with improved leishmanicidal activity: a critical review. Int J Nanomedicine [http:\/\/dx.doi.org\/10.2147\/IJN.S140363]. [PMID: 28794624].2017,12,5289-5311","journal-title":"Int J Nanomedicine"},{"key":"ref=21","volume":"2014","author":"Bilia A.R.","year":"2014","unstructured":"Bilia A.R.; Guccione C.; Isacchi B.; Righeschi C.; Firenzuoli F.; Bergonzi M.C.; Essential oils loaded in nanosystems: a developing strategy for a successful therapeutic approach. Evid Based Complement Alternat Med [http:\/\/dx.doi.org\/10.1155\/2014\/651593]. [PMID: 24971152].2014,2014","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/0-306-46817-4_9","volume":"465","author":"Zarif L.","year":"2000","unstructured":"Zarif L.; Mannino R.J.; Cochleates. Lipid-based vehicles for gene delivery-concept, achievements and future development. Adv Exp Med Biol [http:\/\/dx.doi.org\/10.1007\/0-306-46817-4_9]. [PMID: 10810618].2000,465,83-93","journal-title":"Adv Exp Med Biol"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0169-409X(01)00105-3","volume":"47","author":"Mehnert W.","year":"2001","unstructured":"Mehnert W.; M\u00e4der K.; Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev [http:\/\/dx.doi.org\/10.1016\/S0169-409X(01)00105-3]. [PMID: 11311991].2001,47(2-3),165-196","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.2042-7158.1988.tb05210.x","volume":"40","author":"Hunter C.A.","year":"1988","unstructured":"Hunter C.A.; Dolan T.F.; Coombs G.H.; Baillie A.J.; Vesicular systems (niosomes and liposomes) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis. J Pharm Pharmacol [http:\/\/dx.doi.org\/10.1111\/j.2042-7158.1988.tb05210.x]. [PMID: 2899143].1988,40(3),161-165","journal-title":"J Pharm Pharmacol"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.2042-7158.1986.tb04623.x","volume":"38","author":"Baillie A.J.","year":"1986","unstructured":"Baillie A.J.; Coombs G.H.; Dolan T.F.; Laurie J.; Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconate. J Pharm Pharmacol [http:\/\/dx.doi.org\/10.1111\/j.2042-7158.1986.tb04623.x]. [PMID: 2875149].1986,38(7),502-505","journal-title":"J Pharm Pharmacol"},{"key":"ref=26","doi-asserted-by":"crossref","DOI":"10.1201\/9781315204918","author":"Sharma A.K.","year":"2018","unstructured":"Sharma A.K.; Keservani R.K.; Kesharwani R.K.;  Nanobiomaterials: Applications in Drug Delivery [http:\/\/dx.doi.org\/10.1201\/9781315204918]2018","journal-title":"Nanobiomaterials: Applications in Drug Delivery"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0169-409X(00)00124-1","volume":"47","author":"Kataoka K.","year":"2001","unstructured":"Kataoka K.; Harada A.; Nagasaki Y.; Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev [http:\/\/dx.doi.org\/10.1016\/S0169-409X(00)00124-1]. [PMID: 11251249].2001,47(1),113-131","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/infdis\/jit378","volume":"208","author":"Daftarian P.M.","year":"2013","unstructured":"Daftarian P.M.; Stone G.W.; Kovalski L.; A targeted and adjuvanted nanocarrier lowers the effective dose of liposomal amphotericin B and enhances adaptive immunity in murine cutaneous leishmaniasis. J Infect Dis [http:\/\/dx.doi.org\/10.1093\/infdis\/jit378]. [PMID: 23901083].2013,208(11),1914-1922","journal-title":"J Infect Dis"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1126\/science.1222453","volume":"339","author":"De Volder M.F.","year":"2013","unstructured":"De Volder M.F.; Tawfick S.H.; Baughman R.H.; Hart A.J.; Carbon nanotubes: present and future commercial applications. Science [http:\/\/dx.doi.org\/10.1126\/science.1222453]. [PMID: 23372006].2013,339(6119),535-539","journal-title":"Science"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.tiv.2013.06.002","volume":"27","author":"Jebali A.","year":"2013","unstructured":"Jebali A.; Kazemi B.; Nano-based antileishmanial agents: a toxicological study on nanoparticles for future treatment of cutaneous leishmaniasis. Toxicol In Vitro [http:\/\/dx.doi.org\/10.1016\/j.tiv.2013.06.002]. [PMID: 23806227].2013,27(6),1896-1904","journal-title":"Toxicol In Vitro"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1128\/AAC.30.6.847","volume":"30","author":"Berman J.D.","year":"1986","unstructured":"Berman J.D.; Hanson W.L.; Chapman W.L.; Alving C.R.; Lopez-Berestein G.; Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob Agents Chemother [http:\/\/dx.doi.org\/10.1128\/AAC.30.6.847]. [PMID: 3813512].1986,30(6),847-851","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"N175","DOI":"10.1016\/0968-0004(79)90404-3","volume":"4","author":"Alving C.","year":"1979","unstructured":"Alving C.; Steck E.A.; The use of liposome-encapsulated drugs in leishmaniasis. Trends Biochem Sci [http:\/\/dx.doi.org\/10.1016\/0968-0004(79)90404-3].1979,4(8),N175-N177","journal-title":"Trends Biochem Sci"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ijpharm.2013.07.035","volume":"454","author":"Pham T.T.","year":"2013","unstructured":"Pham T.T.; Loiseau P.M.; Barratt G.; Strategies for the design of orally bioavailable antileishmanial treatments. Int J Pharm [http:\/\/dx.doi.org\/10.1016\/j.ijpharm.2013.07.035]. [PMID: 23871737].2013,454(1),539-552","journal-title":"Int J Pharm"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0014-5793(89)80222-4","volume":"245","author":"Guru P.Y.","year":"1989","unstructured":"Guru P.Y.; Agrawal A.K.; Singha U.K.; Singhal A.; Gupta C.M.; Drug targeting in Leishmania donovani infections using tuftsin-bearing liposomes as drug vehicles. FEBS Lett [http:\/\/dx.doi.org\/10.1016\/0014-5793(89)80222-4]. [PMID: 2538359].1989,245(1-2),204-208","journal-title":"FEBS Lett"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/10611860290007513","volume":"10","author":"Agrawal A.K.","year":"2002","unstructured":"Agrawal A.K.; Agrawal A.; Pal A.; Guru P.Y.; Gupta C.M.; Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters. J Drug Target [http:\/\/dx.doi.org\/10.1080\/10611860290007513]. [PMID: 11996085].2002,10(1),41-45","journal-title":"J Drug Target"},{"key":"ref=36","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/456352","volume":"2013","author":"V\u00e1zquez-Mendoza A.","year":"2013","unstructured":"V\u00e1zquez-Mendoza A.; Carrero J.C.; Rodriguez-Sosa M.; Parasitic infections: a role for C-type lectins receptors. BioMed Res Int [http:\/\/dx.doi.org\/10.1155\/2013\/456352]. [PMID: 23509724].2013,2013","journal-title":"BioMed Res Int"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jac\/38.1.145","volume":"38","author":"Banerjee G.","year":"1996","unstructured":"Banerjee G.; Nandi G.; Mahato S.B.; Pakrashi A.; Basu M.K.; Drug delivery system: Targeting of pentamidines to specific sites using sugar grafted liposomes. J Antimicrob Chemother [http:\/\/dx.doi.org\/10.1093\/jac\/38.1.145]. [PMID: 8858467].1996,38(1),145-150","journal-title":"J Antimicrob Chemother"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/107175400455137","volume":"7","author":"Sinha J.","year":"2000","unstructured":"Sinha J.; Mukhopadhyay S.; Das N.; Basu M.K.; Targeting of liposomal andrographolide to L. donovani-infected macrophages in vivo. Drug Deliv [http:\/\/dx.doi.org\/10.1080\/107175400455137]. [PMID: 11195427].2000,7(4),209-213","journal-title":"Drug Deliv"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1517\/17425247.2014.932347","volume":"11","author":"Azevedo E.G.","year":"2014","unstructured":"Azevedo E.G.; Ribeiro R.R.; da Silva S.M.; Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis. Expert Opin Drug Deliv [http:\/\/dx.doi.org\/10.1517\/17425247.2014.932347]. [PMID: 24962630].2014,11(10),1551-1560","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=40","first-page":"06(03n04)","author":"Liu F","year":"2016","unstructured":"Liu F; Sun Y; Kang C; Hongyan Z.; Pegylated Drug Delivery Systems:\nFrom Design to Biomedical Applications Nano LIFE 2016,06(03n04)","journal-title":"LIFE"},{"key":"ref=41","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/695382","volume":"2011","author":"Jeddi F.","year":"2011","unstructured":"Jeddi F.; Piarroux R.; Mary C.; Antimony resistance in leishmania, focusing on experimental research. J Trop Med [http:\/\/dx.doi.org\/10.1155\/2011\/695382]. [PMID: 22174724].2011,2011","journal-title":"J Trop Med"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ejpb.2015.04.018","volume":"93","author":"Carvalheiro M.","year":"2015","unstructured":"Carvalheiro M.; Esteves M.A.; Santos-Mateus D.; Hemisynthetic trifluralin analogues incorporated in liposomes for the treatment of leishmanial infections. Eur J Pharm Biopharm [http:\/\/dx.doi.org\/10.1016\/j.ejpb.2015.04.018]. [PMID: 25936854].2015,93,346-352","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2147\/IJN.S106548","volume":"12","author":"Want M.Y.","year":"2017","unstructured":"Want M.Y.; Islammudin M.; Chouhan G.; Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis. Int J Nanomedicine [http:\/\/dx.doi.org\/10.2147\/IJN.S106548]. [PMID: 28356736].2017,12,2189-2204","journal-title":"Int J Nanomedicine"},{"key":"ref=44","first-page":"123","volume":"5","author":"Jaiswal M.","year":"2015","unstructured":"Jaiswal M.; Dudhe R.; Sharma P.K.; Nanoemulsion: an advanced mode of drug delivery system 3. Biotech 2015,5(2),123-127","journal-title":"Biotech"},{"key":"ref=45","author":"Rodrigues I.A.","year":"2018","unstructured":"Rodrigues I.A.; Ramos A.S.; Falc\u00e3o D.Q.; Development of Nanoemulsions to Enhance the Antileishmanial Activity of Copaifera paupera Oleoresins. BioMed Res Int [http:\/\/dx.doi.org\/10.1155\/2018\/9781724]. [PMID: 29850595].2018","journal-title":"BioMed Res Int"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"(1): 188-93","DOI":"10.1645\/0022-3395(2001)087[0188:LAOSBL]2.0.CO;2","volume":"87","author":"Afrin F","year":"2001","unstructured":"Afrin F; Dey T; Anam K; Ali N; Leishmanicidal activity of stearylamine-\nbearing liposomes in vitro. J Parasitol [http:\/\/dx.doi.org\/10.1645\/0022-3395(2001)087[0188:LAOSBL]2.0.CO;2]. [PMID: 11227889].2001,87,(1): 188-93","journal-title":"J Parasitol"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1128\/AAC.44.6.1739-1742.2000","volume":"44","author":"Dey T.","year":"2000","unstructured":"Dey T.; Anam K.; Afrin F.; Ali N.; Antileishmanial activities of stearylamine-bearing liposomes. Antimicrob Agents Chemother [http:\/\/dx.doi.org\/10.1128\/AAC.44.6.1739-1742.2000]. [PMID: 10817745].2000,44(6),1739-1742","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejps.2015.01.015","volume":"70","author":"Caldeira L.R.","year":"2015","unstructured":"Caldeira L.R.; Fernandes F.R.; Costa D.F.; Fr\u00e9zard F.; Afonso L.C.; Ferreira L.A.; Nanoemulsions loaded with amphotericin B: a new approach for the treatment of leishmaniasis. Eur J Pharm Sci [http:\/\/dx.doi.org\/10.1016\/j.ejps.2015.01.015]. [PMID: 25660615].2015,70,125-131","journal-title":"Eur J Pharm Sci"},{"key":"ref=49","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6528\/28\/6\/065101","volume":"28","author":"de Oliveira de Siqueira L.B.","year":"2017","unstructured":"de Oliveira de Siqueira L.B.; da Silva Cardoso V.; Rodrigues I.A.; Development and evaluation of zinc phthalocyanine nanoemulsions for use in photodynamic therapy for Leishmania spp. Nanotechnology [http:\/\/dx.doi.org\/10.1088\/1361-6528\/28\/6\/065101]. [PMID: 28071592].2017,28(6)","journal-title":"Nanotechnology"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1080\/14756366.2018.1463221","volume":"33","author":"da Silva Cardoso V.","year":"2018","unstructured":"da Silva Cardoso V.; Vermelho A.B.; Ricci E.; Almeida Rodrigues I.; Mazotto A.M.; Supuran C.T.; Antileishmanial activity of sulphonamide nanoemulsions targeting the \u03b2-carbonic anhydrase from Leishmania species. J Enzyme Inhib Med Chem [http:\/\/dx.doi.org\/10.1080\/14756366.2018.1463221]. [PMID: 29708476].2018,33(1),850-857","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jep.2006.01.020","volume":"106","author":"Kvist L.P.","year":"2006","unstructured":"Kvist L.P.; Christensen S.B.; Rasmussen H.B.; Mejia K.; Gonzalez A.; Identification and evaluation of Peruvian plants used to treat malaria and leishmaniasis. J Ethnopharmacol [http:\/\/dx.doi.org\/10.1016\/j.jep.2006.01.020]. [PMID: 16517108].2006,106(3),390-402","journal-title":"J Ethnopharmacol"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jep.2007.08.007","volume":"114","author":"Estevez Y.","year":"2007","unstructured":"Estevez Y.; Castillo D.; Pisango M.T.; Evaluation of the leishmanicidal activity of plants used by Peruvian Chayahuita ethnic group. J Ethnopharmacol [http:\/\/dx.doi.org\/10.1016\/j.jep.2007.08.007]. [PMID: 17889471].2007,114(2),254-259","journal-title":"J Ethnopharmacol"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1111\/bph.13149","volume":"172","author":"Gupta P.K.","year":"2015","unstructured":"Gupta P.K.; Jaiswal A.K.; Asthana S.; Synergistic enhancement of parasiticidal activity of amphotericin B using copaiba oil in nanoemulsified carrier for oral delivery: an approach for non-toxic chemotherapy. Br J Pharmacol [http:\/\/dx.doi.org\/10.1111\/bph.13149]. [PMID: 25825339].2015,172(14),3596-3610","journal-title":"Br J Pharmacol"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1590\/S0074-02762011000200022","volume":"106","author":"Sesana A.M.","year":"2011","unstructured":"Sesana A.M.; Monti-Rocha R.; Vinhas S.A.; Morais C.G.; Dietze R.; Lemos E.M.; \n                        In vitro activity of amphotericin B cochleates against Leishmania chagasi. Mem Inst Oswaldo Cruz [http:\/\/dx.doi.org\/10.1590\/S0074-02762011000200022]. [PMID: 21537689].2011,106(2),251-253","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1128\/AAC.46.8.2704-2707.2002","volume":"46","author":"Delmas G.","year":"2002","unstructured":"Delmas G.; Park S.; Chen Z.W.; Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. Antimicrob Agents Chemother [http:\/\/dx.doi.org\/10.1128\/AAC.46.8.2704-2707.2002]. [PMID: 12121962].2002,46(8),2704-2707","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=56","first-page":"1799","volume":"9","author":"Monzote L.","year":"2014","unstructured":"Monzote L.; Pi\u00f1\u00f3n A.; Sculli R.; Setzer W.N.; Chemistry and leishmanicidal activity of the essential oil from Artemisia absinthium from Cuba. Nat Prod Commun [http:\/\/dx.doi.org\/10.1177\/1934578X1400901236]. [PMID: 25632489].2014,9(12),1799-1804","journal-title":"Nat Prod Commun"},{"key":"ref=57","volume":"4","author":"Tamargo B.","year":"2017","unstructured":"Tamargo B.; Monzote L.; Pi\u00f1\u00f3n A.; \n                        In Vitro and In Vivo Evaluation of Essential Oil from Artemisia absinthium L. Formulated in Nanocochleates against Cutaneous Leishmaniasis. Medicines (Basel) [http:\/\/dx.doi.org\/10.3390\/medicines4020038]. [PMID: 28930253].2017,4(2)","journal-title":"Medicines (Basel)"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1166\/jbn.2011.1332","volume":"7","author":"Patel P.A.","year":"2011","unstructured":"Patel P.A.; Patravale V.B.; AmbiOnp: solid lipid nanoparticles of amphotericin B for oral administration. J Biomed Nanotechnol [http:\/\/dx.doi.org\/10.1166\/jbn.2011.1332]. [PMID: 22195480].2011,7(5),632-639","journal-title":"J Biomed Nanotechnol"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","volume":"50","author":"M\u00fcller R.H.","year":"2000","unstructured":"M\u00fcller R.H.; M\u00e4der K.; Gohla S.; Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm [http:\/\/dx.doi.org\/10.1016\/S0939-6411(00)00087-4]. [PMID: 10840199].2000,50(1),161-177","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s12010-014-1084-y","volume":"174","author":"Jain V.","year":"2014","unstructured":"Jain V.; Gupta A.; Pawar V.K.; Chitosan-assisted immunotherapy for intervention of experimental leishmaniasis via amphotericin B-loaded solid lipid nanoparticles. Appl Biochem Biotechnol [http:\/\/dx.doi.org\/10.1007\/s12010-014-1084-y]. [PMID: 25106894].2014,174(4),1309-1330","journal-title":"Appl Biochem Biotechnol"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/10611860802528833","volume":"17","author":"Veerareddy P.R.","year":"2009","unstructured":"Veerareddy P.R.; Vobalaboina V.; Ali N.; Antileishmanial activity, pharmacokinetics and tissue distribution studies of mannose-grafted amphotericin B lipid nanospheres. J Drug Target [http:\/\/dx.doi.org\/10.1080\/10611860802528833]. [PMID: 19089691].2009,17(2),140-147","journal-title":"J Drug Target"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bpc.2016.07.005","volume":"217","author":"da Gama Bitencourt J.J.","year":"2016","unstructured":"da Gama Bitencourt J.J.; Pazin W.M.; Ito A.S.; Miltefosine-loaded lipid nanoparticles: Improving miltefosine stability and reducing its hemolytic potential toward erythtocytes and its cytotoxic effect on macrophages. Biophys Chem [http:\/\/dx.doi.org\/10.1016\/j.bpc.2016.07.005]. [PMID: 27497059].2016,217,20-31","journal-title":"Biophys Chem"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1208\/s12249-015-0439-1","volume":"17","author":"Kharaji M.H.","year":"2016","unstructured":"Kharaji M.H.; Doroud D.; Taheri T.; Rafati S.; Drug Targeting to Macrophages With Solid Lipid Nanoparticles Harboring Paromomycin: an In Vitro Evaluation Against L. major and L. tropica. AAPS PharmSciTech [http:\/\/dx.doi.org\/10.1208\/s12249-015-0439-1]. [PMID: 26552399].2016,17(5),1110-1119","journal-title":"AAPS PharmSciTech"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/pim.12340","volume":"38","author":"Heidari-Kharaji M.","year":"2016","unstructured":"Heidari-Kharaji M.; Taheri T.; Doroud D.; Habibzadeh S.; Badirzadeh A.; Rafati S.; Enhanced paromomycin efficacy by solid lipid nanoparticle formulation against Leishmania in mice model. Parasite Immunol [http:\/\/dx.doi.org\/10.1111\/pim.12340]. [PMID: 27213964].2016,38(10),599-608","journal-title":"Parasite Immunol"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/02652048.2011.642016","volume":"29","author":"Pardakhty A.","year":"2012","unstructured":"Pardakhty A.; Shakibaie M.; Daneshvar H.; Khamesipour A.; Mohammadi-Khorsand T.; Forootanfar H.; Preparation and evaluation of niosomes containing autoclaved Leishmania major: a preliminary study. J Microencapsul [http:\/\/dx.doi.org\/10.3109\/02652048.2011.642016]. [PMID: 22150018].2012,29(3),219-224","journal-title":"J Microencapsul"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1146\/annurev.anchem.1.031207.112747","volume":"1","author":"Jesorka A.","year":"2008","unstructured":"Jesorka A.; Orwar O.; Liposomes: technologies and analytical applications. Annu Rev Anal Chem (Palo Alto, Calif) [http:\/\/dx.doi.org\/10.1146\/annurev.anchem.1.031207.112747]. [PMID: 20636098].2008,1,801-832","journal-title":"Annu Rev Anal Chem (Palo Alto, Calif)"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1128\/AAC.42.10.2722","volume":"42","author":"Mullen A.B.","year":"1998","unstructured":"Mullen A.B.; Baillie A.J.; Carter K.C.; Visceral leishmaniasis in the BALB\/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B. Antimicrob Agents Chemother [http:\/\/dx.doi.org\/10.1128\/AAC.42.10.2722]. [PMID: 9756784].1998,42(10),2722-2725","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.etap.2014.04.003","volume":"38","author":"Khazaeli P.","year":"2014","unstructured":"Khazaeli P.; Sharifi I.; Talebian E.; Heravi G.; Moazeni E.; Mostafavi M.; Anti-leishmanial effect of itraconazole niosome on in vitro susceptibility of Leishmania tropica. Environ Toxicol Pharmacol [http:\/\/dx.doi.org\/10.1016\/j.etap.2014.04.003]. [PMID: 24956400].2014,38(1),205-211","journal-title":"Environ Toxicol Pharmacol"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jconrel.2012.04.004","volume":"160","author":"Alsaadi M.","year":"2012","unstructured":"Alsaadi M.; Italia J.L.; Mullen A.B.; The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection. J Control Release [http:\/\/dx.doi.org\/10.1016\/j.jconrel.2012.04.004]. [PMID: 22516093].2012,160(3),685-691","journal-title":"J Control Release"},{"key":"ref=70","first-page":"353","volume":"26","author":"Aflatoonian M.","year":"2016","unstructured":"Aflatoonian M.; Fekri A.; Rahnam Z.; The efficacy of combined topical niosomal dapsone gel and intralesional injection of meglumine antimoniate in comparison with intralesional meglumine antimoniate and cryotherapy in the treatment of cutaneous leishmaniasis. J Pak Assoc Dermatol 2016,26(4),353-360","journal-title":"J Pak Assoc Dermatol"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.actatropica.2018.05.002","volume":"185","author":"Nazari-Vanani R.","year":"2018","unstructured":"Nazari-Vanani R.; Vais R.D.; Sharifi F.; Investigation of anti-leishmanial efficacy of miltefosine and ketoconazole loaded on nanoniosomes. Acta Trop [http:\/\/dx.doi.org\/10.1016\/j.actatropica.2018.05.002]. [PMID: 29733808].2018,185,69-76","journal-title":"Acta Trop"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1039\/C5CS00674K","volume":"45","author":"Guti\u00e9rrez V.","year":"2016","unstructured":"Guti\u00e9rrez V.; Seabra A.B.; Reguera R.M.; Khandare J.; Calder\u00f3n M.; New approaches from nanomedicine for treating leishmaniasis. Chem Soc Rev [http:\/\/dx.doi.org\/10.1039\/C5CS00674K]. [PMID: 26487097].2016,45(1),152-168","journal-title":"Chem Soc Rev"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2217\/nnm.14.116","volume":"10","author":"Barros D.","year":"2015","unstructured":"Barros D.; Costa Lima S.A.; Cordeiro-da-Silva A.; Surface functionalization of polymeric nanospheres modulates macrophage activation: relevance in leishmaniasis therapy. Nanomedicine [http:\/\/dx.doi.org\/10.2217\/nnm.14.116]. [PMID: 25707974].2015,10(3),387-403","journal-title":"Nanomedicine"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jconrel.2003.09.012","volume":"94","author":"Nan A.","year":"2004","unstructured":"Nan A.; Croft S.L.; Yardley V.; Ghandehari H.; Targetable water-soluble polymer-drug conjugates for the treatment of visceral leishmaniasis. J Control Release [http:\/\/dx.doi.org\/10.1016\/j.jconrel.2003.09.012]. [PMID: 14684276].2004,94(1),115-127","journal-title":"J Control Release"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.msec.2015.10.083","volume":"59","author":"Kumar R.","year":"2016","unstructured":"Kumar R.; Sahoo G.C.; Pandey K.; Development of PLGA-PEG encapsulated miltefosine based drug delivery system against visceral leishmaniasis. Mater Sci Eng C [http:\/\/dx.doi.org\/10.1016\/j.msec.2015.10.083]. [PMID: 26652429].2016,59,748-753","journal-title":"Mater Sci Eng C"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jconrel.2012.05.037","volume":"161","author":"Van de Ven H.","year":"2012","unstructured":"Van de Ven H.; Paulussen C.; Feijens P.B.; PLGA nanoparticles and nanosuspensions with amphotericin B: Potent in vitro and in vivo alternatives to Fungizone and AmBisome. J Control Release [http:\/\/dx.doi.org\/10.1016\/j.jconrel.2012.05.037]. [PMID: 22641062].2012,161(3),795-803","journal-title":"J Control Release"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.cyto.2018.05.010","volume":"110","author":"Halder A.","year":"2018","unstructured":"Halder A.; Shukla D.; Das S.; Roy P.; Mukherjee A.; Saha B.; Lactoferrin-modified Betulinic Acid-loaded PLGA nanoparticles are strong anti-leishmanials. Cytokine [http:\/\/dx.doi.org\/10.1016\/j.cyto.2018.05.010]. [PMID: 29784509].2018,110,412-415","journal-title":"Cytokine"},{"key":"ref=78","first-page":"3821","volume":"9","author":"Anand N.","year":"2015","unstructured":"Anand N.; Kanwar R.K.; Dubey M.L.; Effect of lactoferrin protein on red blood cells and macrophages: Mechanism of parasite-host interaction. Drug Des Devel Ther [PMID: 26251568].2015,9,3821-3835","journal-title":"Drug Des Devel Ther"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ejmech.2015.03.022","volume":"95","author":"Souza A.C.","year":"2015","unstructured":"Souza A.C.; Nascimento A.L.; de Vasconcelos N.M.; Activity and in vivo tracking of Amphotericin B loaded PLGA nanoparticles. Eur J Med Chem [http:\/\/dx.doi.org\/10.1016\/j.ejmech.2015.03.022]. [PMID: 25827397].2015,95,267-276","journal-title":"Eur J Med Chem"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.rpor.2013.09.011","volume":"18","author":"Ba\u00f1obre-L\u00f3pez M.","year":"2013","unstructured":"Ba\u00f1obre-L\u00f3pez M.; Teijeiro A.; Rivas J.; Magnetic nanoparticle-based hyperthermia for cancer treatment. Rep Pract Oncol Radiother [http:\/\/dx.doi.org\/10.1016\/j.rpor.2013.09.011]. [PMID: 24416585].2013,18(6),397-400","journal-title":"Rep Pract Oncol Radiother"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.exppara.2013.07.008","volume":"135","author":"de Carvalho R.F.","year":"2013","unstructured":"de Carvalho R.F.; Ribeiro I.F.; Miranda-Vilela A.L.; Leishmanicidal activity of amphotericin B encapsulated in PLGA-DMSA nanoparticles to treat cutaneous leishmaniasis in C57BL\/6 mice. Exp Parasitol [http:\/\/dx.doi.org\/10.1016\/j.exppara.2013.07.008]. [PMID: 23891944].2013,135(2),217-222","journal-title":"Exp Parasitol"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1002\/jbm.b.34058","volume":"106","author":"Scala A.","year":"2018","unstructured":"Scala A.; Piperno A.; Micale N.; \u201cClick\u201d on PLGA-PEG and hyaluronic acid: Gaining access to anti-leishmanial pentamidine bioconjugates. J Biomed Mater Res B Appl Biomater [PMID: 29219244].2018,106(8),2778-2785","journal-title":"J Biomed Mater Res B Appl Biomater"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ijantimicag.2017.01.033","volume":"50","author":"Monteiro L.M.","year":"2017","unstructured":"Monteiro L.M.; L\u00f6benberg R.; Ferreira E.I.; Targeting Leishmania amazonensis amastigotes through macrophage internalisation of a hydroxymethylnitrofurazone nanostructured polymeric system. Int J Antimicrob Agents [http:\/\/dx.doi.org\/10.1016\/j.ijantimicag.2017.01.033]. [PMID: 28454918].2017,50(1),88-92","journal-title":"Int J Antimicrob Agents"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s11671-016-1517-3","volume":"11","author":"do Nascimento T.G.","year":"2016","unstructured":"do Nascimento T.G.; da Silva P.F.; Azevedo L.F.; Polymeric Nanoparticles of Brazilian Red Propolis Extract: Preparation, Characterization, Antioxidant and Leishmanicidal Activity. Nanoscale Res Lett [http:\/\/dx.doi.org\/10.1186\/s11671-016-1517-3]. [PMID: 27316742].2016,11(1),301","journal-title":"Nanoscale Res Lett"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijpharm.2011.08.016","volume":"420","author":"Van de Ven H.","year":"2011","unstructured":"Van de Ven H.; Vermeersch M.; Matheeussen A.; PLGA nanoparticles loaded with the antileishmanial saponin \u03b2-aescin: Factor influence study and in vitro efficacy evaluation. Int J Pharm [http:\/\/dx.doi.org\/10.1016\/j.ijpharm.2011.08.016]. [PMID: 21864661].2011,420(1),122-132","journal-title":"Int J Pharm"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.ijbiomac.2017.07.161","volume":"105","author":"Singh P.K.","year":"2017","unstructured":"Singh P.K.; Pawar V.K.; Jaiswal A.K.; Chitosan coated PluronicF127 micelles for effective delivery of Amphotericin B in experimental visceral leishmaniasis. Int J Biol Macromol [http:\/\/dx.doi.org\/10.1016\/j.ijbiomac.2017.07.161]. [PMID: 28780414].2017,105(Pt 1),1220-1231","journal-title":"Int J Biol Macromol"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.bbamcr.2013.01.006","volume":"1833","author":"Agarwal S.","year":"2013","unstructured":"Agarwal S.; Rastogi R.; Gupta D.; Patel N.; Raje M.; Mukhopadhyay A.; Clathrin-mediated hemoglobin endocytosis is essential for survival of Leishmania. Biochim Biophys Acta [http:\/\/dx.doi.org\/10.1016\/j.bbamcr.2013.01.006]. [PMID: 23328080].2013,1833(5),1065-1077","journal-title":"Biochim Biophys Acta"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1074\/jbc.M411845200","volume":"280","author":"Krishnamurthy G.","year":"2005","unstructured":"Krishnamurthy G.; Vikram R.; Singh S.B.; Hemoglobin receptor in Leishmania is a hexokinase located in the flagellar pocket. J Biol Chem [http:\/\/dx.doi.org\/10.1074\/jbc.M411845200]. [PMID: 15579464].2005,280(7),5884-5891","journal-title":"J Biol Chem"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.actatropica.2016.02.026","volume":"158","author":"Bose P.P.","year":"2016","unstructured":"Bose P.P.; Kumar P.; Dwivedi M.K.; Hemoglobin guided nanocarrier for specific delivery of amphotericin B to Leishmania infected macrophage. Acta Trop [http:\/\/dx.doi.org\/10.1016\/j.actatropica.2016.02.026]. [PMID: 26945483].2016,158,148-159","journal-title":"Acta Trop"},{"key":"ref=90","doi-asserted-by":"crossref","DOI":"10.4172\/1920-4159.1000212","volume":"8","author":"Kumar P.","year":"2016","unstructured":"Kumar P.; Bose P.P.; Targeted Delivery of Paromomycin to Leishmania Infected Macrophage by Hemoglobin Tagged Nanocarrier. J App Pharm [http:\/\/dx.doi.org\/10.4172\/1920-4159.1000212].2016,8(212)","journal-title":"J App Pharm"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.exppara.2018.02.003","volume":"186","author":"Mendon\u00e7a D.V.C.","year":"2018","unstructured":"Mendon\u00e7a D.V.C.; Martins V.T.; Lage D.P.; Comparing the therapeutic efficacy of different amphotericin B-carrying delivery systems against visceral leishmaniasis. Exp Parasitol [http:\/\/dx.doi.org\/10.1016\/j.exppara.2018.02.003]. [PMID: 29448040].2018,186,24-35","journal-title":"Exp Parasitol"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.parint.2016.07.005","volume":"65","author":"Duarte M.C.","year":"2016","unstructured":"Duarte M.C.; Lage L.M.; Lage D.P.; Treatment of murine visceral leishmaniasis using an 8-hydroxyquinoline-containing polymeric micelle system. Parasitol Int [http:\/\/dx.doi.org\/10.1016\/j.parint.2016.07.005]. [PMID: 27425599].2016,65(6 Pt A),728-736","journal-title":"Parasitol Int"},{"key":"ref=93","author":"Sk U.H.","year":"2017","unstructured":"Sk U.H.; Antimicrobial Nanoarchitectonics: From Synthesis To Applications. Chapter 12: Nanosize Dendrimers: Potential Use as Carriers and Antimicrobials. Oxford, United Kingdom: Elsevier Inc 2017"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s11030-013-9467-5","volume":"17","author":"Giarolla J.","year":"2013","unstructured":"Giarolla J.; Pasqualoto K.F.; Ferreira E.I.; Design and exploratory data analysis of a second generation of dendrimer prodrugs potentially antichagasic and leishmanicide. Mol Divers [http:\/\/dx.doi.org\/10.1007\/s11030-013-9467-5]. [PMID: 23990201].2013,17(4),711-720","journal-title":"Mol Divers"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1080\/08927022.2014.994622","volume":"41","author":"da Silva Santos S.","year":"2015","unstructured":"da Silva Santos S.; Giarolla J.; Pasqualoto K.F.; Ferreira E.I.; \n                        In silico study to analyse the disassembly of quercetin-targeted dendrimers potentially leishmanicide. Mol Simul [http:\/\/dx.doi.org\/10.1080\/08927022.2014.994622].2015,41(18),1495-1508","journal-title":"Mol Simul"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1128\/AAC.04213-14","volume":"59","author":"Jain K.","year":"2015","unstructured":"Jain K.; Verma A.K.; Mishra P.R.; Jain N.K.; Surface-engineered dendrimeric nanoconjugates for macrophage-targeted delivery of amphotericin B: formulation development and in vitro and in vivo evaluation. Antimicrob Agents Chemother [http:\/\/dx.doi.org\/10.1128\/AAC.04213-14]. [PMID: 25645852].2015,59(5),2479-2487","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=97","year":"2014","unstructured":"Caballero A, Salas, JM, S\u00e1nchez-Moreno, M 2014","journal-title":"Caballero A, Salas, JM, S\u00e1nchez-Moreno, M"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.drudis.2010.10.005","volume":"15","author":"Navarro M.","year":"2010","unstructured":"Navarro M.; Gabbiani C.; Messori L.; Gambino D.; Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives. Drug Discov Today [http:\/\/dx.doi.org\/10.1016\/j.drudis.2010.10.005]. [PMID: 20974285].2010,15(23-24),1070-1078","journal-title":"Drug Discov Today"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1039\/b924677k","volume":"2","author":"Fricker S.P.","year":"2010","unstructured":"Fricker S.P.; Cysteine proteases as targets for metal-based drugs. Metallomics [http:\/\/dx.doi.org\/10.1039\/b924677k]. [PMID: 21072382].2010,2(6),366-377","journal-title":"Metallomics"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.jinorgbio.2008.05.010","volume":"102","author":"Fricker S.P.","year":"2008","unstructured":"Fricker S.P.; Mosi R.M.; Cameron B.R.; Metal compounds for the treatment of parasitic diseases. J Inorg Biochem [http:\/\/dx.doi.org\/10.1016\/j.jinorgbio.2008.05.010]. [PMID: 18684510].2008,102(10),1839-1845","journal-title":"J Inorg Biochem"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.tmaid.2006.09.004","volume":"5","author":"Minodier P.","year":"2007","unstructured":"Minodier P.; Parola P.; Cutaneous leishmaniasis treatment. Travel Med Infect Dis [http:\/\/dx.doi.org\/10.1016\/j.tmaid.2006.09.004]. [PMID: 17448941].2007,5(3),150-158","journal-title":"Travel Med Infect Dis"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1590\/S0074-02761998000600025","volume":"93","author":"Najim R.A.","year":"1998","unstructured":"Najim R.A.; Sharquie K.E.; Farjou I.B.; Zinc sulphate in the treatment of cutaneous leishmaniasis: an in vitro and animal study. Mem Inst Oswaldo Cruz [http:\/\/dx.doi.org\/10.1590\/S0074-02761998000600025]. [PMID: 9921312].1998,93(6),831-837","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref=103","doi-asserted-by":"crossref","DOI":"10.5812\/jjm.11192","volume":"7","author":"Fattahi Bafghi A.","year":"2014","unstructured":"Fattahi Bafghi A.; Noorbala M.; Noorbala M.T.; Aghabagheri M.; Anti Leishmanial Effect of Zinc Sulphate on the Viability of Leishmania tropica and L. major Promastigotes. Jundishapur J Microbiol [http:\/\/dx.doi.org\/10.5812\/jjm.11192]. [PMID: 25485055].2014,7(9)","journal-title":"Jundishapur J Microbiol"},{"key":"ref=104","first-page":"734","volume":"29","author":"Sharquie K.E.","year":"2008","unstructured":"Sharquie K.E.; Najim R.A.; Al-Hayani R.K.; Al-Nuaimy A.A.; Maroof D.M.; The therapeutic and prophylactic role of oral zinc sulfate in management of recurrent aphthous stomatitis (ras) in comparison with dapsone. Saudi Med J [PMID: 18454224].2008,29(5),734-738","journal-title":"Saudi Med J"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000078586","volume":"209","author":"Iraji F.","year":"2004","unstructured":"Iraji F.; Vali A.; Asilian A.; Shahtalebi M.A.; Momeni A.Z.; Comparison of intralesionally injected zinc sulfate with meglumine antimoniate in the treatment of acute cutaneous leishmaniasis. Dermatology (Basel) [http:\/\/dx.doi.org\/10.1159\/000078586]. [PMID: 15237267].2004,209(1),46-49","journal-title":"Dermatology (Basel)"},{"key":"ref=106","first-page":"73","volume":"4","author":"Firooz A.","year":"2005","unstructured":"Firooz A.; Khatami A.; Khamesipour A.; Intralesional injection of 2% zinc sulfate solution in the treatment of acute old world cutaneous leishmaniasis: A randomized, double-blind, controlled clinical trial. J Drugs Dermatol [PMID: 15696988].2005,4(1),73-79","journal-title":"J Drugs Dermatol"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00580-012-1561-z","volume":"23","author":"Soflaei S.","year":"2014","unstructured":"Soflaei S.; Dalimi A.; Abdoli A.; Anti-leishmanial activities of selenium nanoparticles and selenium dioxide on Leishmania infantum. Comp Clin Pathol [http:\/\/dx.doi.org\/10.1007\/s00580-012-1561-z].2014,23(1),15-20","journal-title":"Comp Clin Pathol"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1007\/s11095-016-1985-2","volume":"33","author":"Chaurasia M.","year":"2016","unstructured":"Chaurasia M.; Singh P.K.; Jaiswal A.K.; Bioinspired Calcium Phosphate Nanoparticles Featuring as Efficient Carrier and Prompter for Macrophage Intervention in Experimental Leishmaniasis. Pharm Res [http:\/\/dx.doi.org\/10.1007\/s11095-016-1985-2]. [PMID: 27401407].2016,33(11),2617-2629","journal-title":"Pharm Res"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.parint.2014.07.008","volume":"63","author":"Saudagar P.","year":"2014","unstructured":"Saudagar P.; Dubey V.K.; Carbon nanotube based betulin formulation shows better efficacy against Leishmania parasite. Parasitol Int [http:\/\/dx.doi.org\/10.1016\/j.parint.2014.07.008]. [PMID: 25086374].2014,63(6),772-776","journal-title":"Parasitol Int"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/jac\/dkr002","volume":"66","author":"Prajapati V.K.","year":"2011","unstructured":"Prajapati V.K.; Awasthi K.; Gautam S.; Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes. J Antimicrob Chemother [http:\/\/dx.doi.org\/10.1093\/jac\/dkr002]. [PMID: 21393222].2011,66(4),874-879","journal-title":"J Antimicrob Chemother"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/infdis\/jir735","volume":"205","author":"Prajapati V.K.","year":"2012","unstructured":"Prajapati V.K.; Awasthi K.; Yadav T.P.; Rai M.; Srivastava O.N.; Sundar S.; An oral formulation of amphotericin B attached to functionalized carbon nanotubes is an effective treatment for experimental visceral leishmaniasis. J Infect Dis [http:\/\/dx.doi.org\/10.1093\/infdis\/jir735]. [PMID: 22158723].2012,205(2),333-336","journal-title":"J Infect Dis"},{"key":"ref=112","first-page":"6891","volume":"10","author":"Nadhman A.","year":"2015","unstructured":"Nadhman A.; Nazir S.; Khan M.I.; Visible-light-responsive ZnCuO nanoparticles: benign photodynamic killers of infectious protozoans. Int J Nanomedicine [PMID: 26604755].2015,10,6891-6903","journal-title":"Int J Nanomedicine"},{"key":"ref=113","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.freeradbiomed.2014.09.005","volume":"77","author":"Nadhman A.","year":"2014","unstructured":"Nadhman A.; Nazir S.; Khan M.I.; PEGylated silver doped zinc oxide nanoparticles as novel photosensitizers for photodynamic therapy against Leishmania. Free Radic Biol Med [http:\/\/dx.doi.org\/10.1016\/j.freeradbiomed.2014.09.005]. [PMID: 25266330].2014,77,230-238","journal-title":"Free Radic Biol Med"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jphotobiol.2016.05.003","volume":"161","author":"Ahmad A.","year":"2016","unstructured":"Ahmad A.; Wei Y.; Syed F.; \n                        Isatis tinctoria mediated synthesis of amphotericin B-bound silver nanoparticles with enhanced photoinduced antileishmanial activity: A novel green approach. J Photochem Photobiol B [http:\/\/dx.doi.org\/10.1016\/j.jphotobiol.2016.05.003]. [PMID: 27203567].2016,161,17-24","journal-title":"J Photochem Photobiol B"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.msec.2017.02.145","volume":"75","author":"Kumar R.","year":"2017","unstructured":"Kumar R.; Pandey K.; Sahoo G.C.; Development of high efficacy peptide coated iron oxide nanoparticles encapsulated amphotericin B drug delivery system against visceral leishmaniasis. Mater Sci Eng C [http:\/\/dx.doi.org\/10.1016\/j.msec.2017.02.145]. [PMID: 28415438].2017,75,1465-1471","journal-title":"Mater Sci Eng C"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.micpath.2017.07.009","volume":"110","author":"Ahmad A.","year":"2017","unstructured":"Ahmad A.; Wei Y.; Ullah S.; Synthesis of phytochemicals-stabilized gold nanoparticles and their biological activities against bacteria and Leishmania. Microb Pathog [http:\/\/dx.doi.org\/10.1016\/j.micpath.2017.07.009]. [PMID: 28705747].2017,110,304-312","journal-title":"Microb Pathog"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/172933","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T03:41:09Z","timestamp":1568950869000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/172933\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,16]]},"references-count":116,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2019,8,16]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612825666190621154552","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8,16]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-05-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}